CG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programs - CGON News | RalliesCG Oncology publishes investor deck highlighting cretostimogene data in high-risk NMIBC programs
C
CGON• Investor deck highlights Phase 3 cretostimogene data
- CG Oncology highlighted Phase 3 BOND-003 Cohort C in high-risk BCG-unresponsive CIS, reporting 76% complete response at any time.
- Durability metrics showed 46.4% complete response at 12 months and 41.8% at 24 months, with 90% of 12-month responders remaining in response.
- Safety update cited zero grade 3+ treatment-related adverse events or deaths, with most adverse events grade 1-2.
- Phase 3 BOND-003 Cohort P in high-risk BCG-unresponsive Ta/T1 reported high-grade event-free survival of 95.7% at 3 months and 84.6% at 6 months.
- Manufacturing readiness noted current capacity of 40,000-50,000 vials per year, with a 10x scale-up process underway.
